Acta Scientific PAEDIATRICS (ISSN: 2581-883X)

Case Report Volume 5 Issue 10

Anaphylactic Reaction in a Child After Dose of Pfizer-BioNTech COVID-19 Vaccine

Reem W Alreshidi1, Malik Almalki1*, Shaker Alreshidi2 and Mohammad Almalki3

1Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
2King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
3King Saud Medical City, Riyadh, Saudi Arabia

*Corresponding Author: Malik Almalki, Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

Received: July 05, 2022; Published: September 28, 2022

Abstract

Purpose: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected millions of people of all ages worldwide to date. The majority of confirmed cases were among adults and approximately 2% of the confirmed cases are for children. Covid-19 vaccine had high safety and efficacy. Nevertheless, adverse reaction has been reported, approximately 90% of all vaccine recipients reported local and at least one systemic reaction. In this case report, we report a case of anaphylactic reaction in a child after dose of Pfizer-BioNTech COVID-19 vaccine. Up to our knowledge, this is the first case to be reported of anaphylactic reaction in a child after dose of Pfizer-BioNTech COVID-19 vaccine

Observations: A 13 year old boy, presented to our paediatric emergency department (PED) with anaphylactic reaction, complaint of rash and shortness of breath (SOB) 13 minutes after received first dose Pfizer-BioNTech COVID-19 vaccine. management involved systemic epinephrine, antihistamine and steroid.

Conclusions and Importance: Due to the recent authorization of COVID-19 vaccine in children of 12 years or older, children with anaphylaxis post- vaccination are expected. In addition to the necessary observation at vaccine centre, necessary supplies to immediately manage anaphylaxis, should be available in vaccination centres.

Keywords: COVID-19; Vaccine; Allergy; Anaphylaxis; Paediatric; Adverse Effect

References

  1. WHO Records COVID-19.
  2. Shekerdemian LS., et al. “Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units”. JAMA Pediatric 174 (2020): 868-873.
  3. Dong Y., et al. “Epidemiology of COVID-19 among children in China”. Pediatrics 145 (2020): e20200702.
  4. Liguoro I., et al. “SARS-COV-2 infection in children and newborns: a systematic review”. European Journal of Pediatrics 179 (2020): 1029-1046.
  5. YM Kazzaz., et al. “Hospital preparedness and management of pediatric population during COVID-19 outbreak”. Annals of Thoracic Medicine 15 (2020): 107-117.
  6. Ministry of MOH Records COVID-19.
  7. Frenck RW., et al. “C4591001 Clinical Trial Group. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents”. The New England Journal of Medicine 3 (2021): 239-250.
  8. Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Pfizer-BioNTech COVID-19 Vaccine, CDC (2021).
  9. Shimabukuro T and Nair N. “Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine”. JAMA 8 (2021): 780-781.
  10. Rüggeberg JU., et al. “Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data”. Vaccine31 (2007): 5675-5684.
  11. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021”. Morbidity and Mortality Weekly Report 70 (2020): 125-129.
  12. Polack FP., et al. “C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine”. The New England Journal of Medicine 27 (2020): 2603-2615.
  13. Rüggeberg JU., et al. Brighton Collaboration Anaphylaxis Working Group. “Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data”. Vaccine 25 (2007): 5675-5684.
  14.  

Citation

Citation: Malik Almalki., et al. “Anaphylactic Reaction in a Child After Dose of Pfizer-BioNTech COVID-19 Vaccine". Acta Scientific Paediatrics 5.10 (2022): 13-15.

Copyright

Copyright: © 2022 Malik Almalki., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate33%
Acceptance to publication20-30 days
Impact Factor1.197

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 15, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US